


Amendment to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-19. Cancelled

20. (NEW) A compound represented by the following general formula (1) or a pharmacologically acceptable salt thereof:




wherein

n_1 , n_2 , and n_3 represent an integer of 1;

R_1 , R_2 , R_3 , R_4 , R_5 , and R_6 each independently represent a hydrogen atom;

A_1 and A_2 each independently represent a hydrogen atom, a substitutable monocyclic or polycyclic heteroaromatic ring, a partly saturated substitutable polycyclic heteroaromatic ring, a substitutable monocyclic or polycyclic aromatic ring, a partially saturated substitutable polycyclic aromatic ring, a substitutable heteroring, or a group represented by the following formula (2):



wherein

R₇, R₈, R₉, and R₁₀ each independently represent a hydrogen atom, a substitutable alkyl group having 1 to 15 carbon atoms, a substitutable alkenyl group having 2 to 15 carbon atoms, a substitutable alkynyl group having 2 to 15 carbon atoms, or a substitutable cyclic alkyl group having 3 to 15 carbon atoms;

W represents a phenyl group;

X represents CH₂;

D represents a group represented by the following formula (6):



wherein

Q represents NR₁₂, wherein R₁₂ represents -(CH₂)_mCOOR₃₆, wherein m represents an integer of 1 or 2 and R₃₆ represents a hydrogen atom or an alkyl group having 1 to 5 carbon atoms;

Y represents -(CH₂)_{m3}- wherein m3 represents an integer of 0 to 6; and

B represents NR₂₅R₂₆ wherein R₂₅ and R₂₆ each independently represent a

hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or a cyclic alkyl group having 3 to 6 carbon atoms.

21. (NEW) A compound and a pharmacologically acceptable salt thereof according to claim 20, wherein A₁ is an imidazole group and A₂ is an imidazole group or an imidazole group substituted with an alkyl group.

22. (NEW) A compound and a pharmacologically acceptable salt thereof according to claim 20, wherein R₃₆ represents a hydrogen atom or an ethyl group.

23. (NEW) A compound or a pharmacologically acceptable salt thereof according to claim 20, wherein R₂₅ and R₂₆ represent an alkyl group having 1 to 6 carbon atoms.

24. (NEW) A compound or a pharmacologically acceptable salt thereof according to claim 20, wherein the compound is selected from the group consisting of:

3-[(4-dipropylamino-butyl)-(4-{{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzyl)-amino]-propionic acid,
[(4-dipropylamino-butyl)-(4-{{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzyl)-amino]-acetic acid, and

[[4-(dipropyl-amino)-butyl]- (4-[[1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl]-benzyl)-amino]-acetic acid ethyl ester.

25. (NEW) A medical composition, comprising as an active ingredient the compound, or the pharmacologically acceptable salt thereof, according to claim 20.

26. (NEW) A CXCR4 antagonist, comprising as an active ingredient the compound, or the pharmacologically acceptable salt thereof according to claim 20.

27. (NEW) An antiviral drug, comprising as an active ingredient the compound, or the pharmacologically acceptable salt thereof according to claim 20.

28. (NEW) A rheumatic disease ameliorating agent based on a CXCR4 antagonism, comprising as an active ingredient the compound, or the pharmacologically acceptable salt thereof, according to claim 20.

29. (NEW) A cancer metastatic disease ameliorating agent based on a CXCR4 antagonism, comprising as an active ingredient the compound, or the pharmacologically acceptable salt thereof according to claim 20.

30. (NEW) A method of treating a cancer metastatic disease comprising administering the compound or the pharmacologically acceptable salt thereof according to claim 20.

31. (NEW) A method of treating a rheumatic disease comprising administering the compound or the pharmacologically acceptable salt thereof according to claim 20.

32. (NEW) A compound or a pharmacologically acceptable salt thereof according to claim 24, wherein the compound is 3-[(4-dipropylamino-butyl)-(4-{{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzyl)-amino]-propionic acid.

33. (NEW) A compound or a pharmacologically acceptable salt thereof according to claim 24, wherein the compound is [(4-dipropylamino-butyl)-(4-{{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzyl)-amino]-acetic acid.

34. (NEW) A compound or a pharmacologically acceptable salt thereof according to claim 24, wherein the compound is [[4-(dipropyl-amino)-butyl]-{(4-[[1H-

SAITOU et al. - Serial No. 10/591,722
Amendment Under 37 C.F.R. 1.111 And Record of Telephonic Interview
Attorney Docket: MOEG-P100

imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl]-benzyl)-
amino]-acetic acid ethyl ester.